title: [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
abstract: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease, it's pathogenic mechanism is unknown and there is a lack of safe and effective therapeutic drug on RA. Because of important function of B cells in RA pathogenic mechanism, many therapeutic drugs targeted on different positions of B cells are emerging in RA therapy. These B cell-targeted therapeutic biologic agents include anti-CD20 monoclonal antibody (such as rituximab, ocrelizumab and ofatumumab), biologic agents which targeted B lymphocyte stimulator (BLyS) and their receptors (such as belimumab and atacicept), anti-CD22 monoclonal antibody and CD40/CD40L co-stimulation reaction blocker. Efficacy of above-mentioned targeting agents has confirmed in studies of RA and it's animal models, suggesting that it is a promising therapeutic strategy that B cells are regarded as targeting position in RA therapy.
authors.affiliation: Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immunopharmacology of Education Ministry of China, Hefei 230032, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Di
authors.forename: Yan
authors.initials: Y
authors.lastname: Chang
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Wu
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D053264:B-Cell Activating Factor / Q000494:pharmacology / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D053264:B-Cell Activating Factor; D000069283:Rituximab; C511911:belimumab